During a hereditary angioedema (HAE) attack, your body produces too much of a protein called bradykinin.1–5 In large quantities, this protein causes fluid in the blood vessels to leak into the surrounding area, causing painful and sometimes disfiguring swelling.1–6 SAJAZIR works by preventing bradykinin from attaching to receptors found on the lining of blood vessels, which limits their activity and reduces the symptoms of the HAE attack.6

Talk to your doctor and ask them to download, complete and fax an enrollment form and write your prescription for SAJAZIR (specifying the brand name), including any special instructions required by your state (e.g. “dispense as written”). The rules for dispensing branded products vary by state and your doctor should be aware of precisely what is needed to complete your prescription and enrollment form.

Let your doctor know about any other medical conditions you have, or any other medication you are taking.6 SAJAZIR has not been evaluated in pregnant or breastfeeding women, so if you are pregnant or planning to be, or breastfeeding or planning to, you should tell your doctor.6

Before you start treatment with SAJAZIR, you have the option to receive a training pack and thorough 1-to-1 training on how to administer SAJAZIR.6 One of our registered product support nurses will take you through the process step-by-step until you are fully confident and capable to administer it on your own in the future.

As soon as you recognize the symptoms of a hereditary angioedema (HAE) attack, you should administer SAJAZIR.6 However, if you still have symptoms after your SAJAZIR injection, or they return, additional SAJAZIR doses can be taken at least 6 hours apart. You should not use more than 3 doses in a 24-hour period.6


  1. Maurer M, et al. Allergy. 2018;73(8):1575–1596.
  2. Zuraw BL, et al. J Allergy Clin Immunol Pract. 2013;1(5):458–467.
  3. El-Shanawany T. Hereditary Angioedema. British Society for Immunology. https://www.immunology.org/public-information/bitesized-immunology/immune-dysfunction/hereditary-angioedema (accessed October 2021).
  4. Ghazi A, Grant JA. Biologics. 2013;7:103–113.
  5. Lumry W, et al. Journal of Infusion Nursing, 2020;43(3):134–145.
  6. SAJAZIR™ (icatibant) Injection. Prescribing Information. Cycle Pharmaceuticals Limited.

Indication and Important Safety Information

SAJAZIR™ (Icatibant) injection is a medicine used to treat acute attacks of hereditary angioedema (HAE) in adults 18 years of age and older.

Laryngeal attacks can become life threatening. If you have an HAE attack of the throat (laryngeal attack), inject SAJAZIR and then go to the nearest hospital emergency room right away.

The most common side effects of SAJAZIR include:

  • redness, bruising, swelling, warmth, burning, itching, irritation, hives, numbness, pressure, or pain at the injection site
  • fever
  • too much of an enzyme called transaminase in your blood
  • dizziness
  • nausea
  • headache
  • rash

These are not all of the possible side effects of SAJAZIR. Tell your healthcare provider if you have any side effects.

Also tell your healthcare provider if you have any other medical conditions, are breastfeeding or plan to breastfeed, or if you are pregnant or planning to become pregnant. SAJAZIR has not been evaluated in pregnant or nursing women. You and your healthcare provider will decide if SAJAZIR is right for you.

If your symptoms continue or come back, you may repeat your SAJAZIR injection at least 6 hours apart. Do not use more than 3 doses of SAJAZIR in a 24-hour period.

Tiredness, drowsiness, and dizziness have been reported following the use of SAJAZIR. If this occurs, do not drive a car, use machinery, or do anything that needs you to be alert.

For more detailed information, please refer to the Full Prescribing Information.

To report SUSPECTED ADVERSE REACTIONS contact Cycle Pharmaceuticals at 1-800-836-4380, or the FDA at: 1-800-FDA-1088 or www.fda.gov/medwatch.